CTOs on the Move

Spark Therapeutics

www.sparktx.com

 
At Spark Therapeutics, we don`t follow footsteps. We create the path. We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. Our mission is seemingly impossible to others, but not to us: Challenge the inevitability of genetic disease by discovering, developing and delivering treatments in ways unimaginable – until now. Since our founding, we have been committed to bringing a wide range of expertise to build a fully integrated gene therapy company focused on inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.sparktx.com
  • 3737 Market Street
    Philadelphia, PA USA 19104
  • Phone: 215.220.9300

Executives

Name Title Contact Details
Scott Strahler
 Chief Information Officer (CIO) North America Profile
Amy Shillingford
 Head of Information Technology Profile
Cynthia Pussinen
 Chief Technical Officer Profile

Similar Companies

Howell and Haferkamp

Howell and Haferkamp, L.C. is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aytu BioScience

Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company`s therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients` redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company`s strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.

http://www.katumbas.com/

http://www.katumbas.com/ is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Imara

Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.

PrecisionMed

PrecisionMed Inc. is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.